Literature DB >> 21896905

Enhanced neutralization of HIV by antibodies displayed on the S-layer of Caulobacter crescentus.

Mark Duval1, Christopher J Lewis, John F Nomellini, Marc S Horwitz, John Smit, Lisa A Cavacini.   

Abstract

Innovative methods of prevention are needed to stop the more than two million new HIV-1 infections annually, particularly in women. Local application of anti-HIV antibodies has been shown to be effective at preventing infection in nonhuman primates; however, the concentrations needed are cost prohibitive. Display of antibodies on a particulate platform will likely prolong effectiveness of these anti-HIV agents and lower the cost of goods. Here, we demonstrate that the bacterium Caulobacter crescentus and its highly expressed surface-layer (S-layer) protein can provide this antibody display platform. Caulobacters displaying protein G, alone or with CD4 codisplay, successfully captured HIV-1-specific antibodies and demonstrated functional neutralization. Compared to soluble antibodies, a neutralizing anti-HIV antibody displayed on Caulobacter was as effective or more effective at neutralizing diverse HIV-1 isolates. Moreover, when an antibody reactive with an epitope induced by CD4 binding (CD4i) was codisplayed with CD4, there was significant enhancement in HIV-1 neutralization. These results suggest that caulobacters displaying anti-HIV antibodies offer a distinct improvement in the use of antibodies as microbicides. Furthermore, these reagents can specifically evaluate anti-HIV antibodies in concert with other HIV-1 blocking agents to assess the most suitable tools for conversion to scFvs, allowing for direct display within the S-layer protein and further reducing cost of goods. In summary, C. crescentus, which can be easily produced and chemically stabilized at low cost, is well suited for engineering as an effective platform, offering an inexpensive way to produce and deliver HIV-1-specific microbicides.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21896905      PMCID: PMC3232825          DOI: 10.1128/AAC.00509-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  38 in total

Review 1.  Preclinical evaluation of anti-HIV microbicide products: New models and biomarkers.

Authors:  Gustavo F Doncel; Meredith R Clark
Journal:  Antiviral Res       Date:  2010-12       Impact factor: 5.970

2.  Control of the microbial flora of the vagina by H2O2-generating lactobacilli.

Authors:  S J Klebanoff; S L Hillier; D A Eschenbach; A M Waltersdorph
Journal:  J Infect Dis       Date:  1991-07       Impact factor: 5.226

3.  Conformational changes in env oligomer induced by an antibody dependent on the V3 loop base.

Authors:  Lisa Cavacini; Mark Duval; Leslie Song; Rebecca Sangster; Shi-hua Xiang; Joseph Sodroski; Marshall Posner
Journal:  AIDS       Date:  2003-03-28       Impact factor: 4.177

4.  Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5.

Authors:  Michael M Lederman; Ronald S Veazey; Robin Offord; Donald E Mosier; Jason Dufour; Megan Mefford; Michael Piatak; Jeffrey D Lifson; Janelle R Salkowitz; Benigno Rodriguez; Andrew Blauvelt; Oliver Hartley
Journal:  Science       Date:  2004-10-15       Impact factor: 47.728

5.  Isolation and comparison of the paracrystalline surface layer proteins of freshwater caulobacters.

Authors:  S G Walker; S H Smith; J Smit
Journal:  J Bacteriol       Date:  1992-03       Impact factor: 3.490

6.  Periodic surface array in Caulobacter crescentus: fine structure and chemical analysis.

Authors:  J Smit; D A Grano; R M Glaeser; N Agabian
Journal:  J Bacteriol       Date:  1981-06       Impact factor: 3.490

7.  Transformation of freshwater and marine caulobacters by electroporation.

Authors:  A Gilchrist; J Smit
Journal:  J Bacteriol       Date:  1991-01       Impact factor: 3.490

8.  Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies--implications for acquired immunodeficiency syndrome vaccine.

Authors:  Flavia Ferrantelli; Moiz Kitabwalla; Robert A Rasmussen; Chuanhai Cao; Ting-Chao Chou; Hermann Katinger; Gabriela Stiegler; Lisa A Cavacini; Yun Bai; Joseph Cotropia; Kenneth E Ugen; Ruth M Ruprecht
Journal:  J Infect Dis       Date:  2003-12-31       Impact factor: 5.226

9.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

Authors:  P Roben; J P Moore; M Thali; J Sodroski; C F Barbas; D R Burton
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

10.  Cloning of the major protein of the Caulobacter crescentus periodic surface layer: detection and characterization of the cloned peptide by protein expression assays.

Authors:  J Smit; N Agabian
Journal:  J Bacteriol       Date:  1984-12       Impact factor: 3.490

View more
  7 in total

Review 1.  Engineering commensal bacteria for prophylaxis against infection.

Authors:  Yih-Lin Goh; HongFei He; John C March
Journal:  Curr Opin Biotechnol       Date:  2012-03-28       Impact factor: 9.740

Review 2.  Human Microbiome Engineering: The Future and Beyond.

Authors:  Arunava Kali
Journal:  J Clin Diagn Res       Date:  2015-09-01

3.  Bioadsorption of Rare Earth Elements through Cell Surface Display of Lanthanide Binding Tags.

Authors:  Dan M Park; David W Reed; Mimi C Yung; Ali Eslamimanesh; Malgorzata M Lencka; Andrzej Anderko; Yoshiko Fujita; Richard E Riman; Alexandra Navrotsky; Yongqin Jiao
Journal:  Environ Sci Technol       Date:  2016-02-16       Impact factor: 9.028

4.  Engineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models.

Authors:  In Young Hwang; Elvin Koh; Adison Wong; John C March; William E Bentley; Yung Seng Lee; Matthew Wook Chang
Journal:  Nat Commun       Date:  2017-04-11       Impact factor: 14.919

5.  Generation of a Dual-Target, Safe, Inexpensive Microbicide that Protects Against HIV-1 and HSV-2 Disease.

Authors:  Christina Farr Zuend; John F Nomellini; John Smit; Marc S Horwitz
Journal:  Sci Rep       Date:  2018-02-12       Impact factor: 4.379

Review 6.  Synthetic Biology Approaches in The Development of Engineered Therapeutic Microbes.

Authors:  Minjeong Kang; Donghui Choe; Kangsan Kim; Byung-Kwan Cho; Suhyung Cho
Journal:  Int J Mol Sci       Date:  2020-11-19       Impact factor: 5.923

7.  Development of an HIV-1 Microbicide Based on Caulobacter crescentus: Blocking Infection by High-Density Display of Virus Entry Inhibitors.

Authors:  Christina Farr; John F Nomellini; Evan Ailon; Iryna Shanina; Sassan Sangsari; Lisa A Cavacini; John Smit; Marc S Horwitz
Journal:  PLoS One       Date:  2013-06-19       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.